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Abstract
Significance: Inflammation increases during the ageing process. It is linked to mitochondrial
dysfunction  and  increased  ROS  production.  Mitochondrial  macromolecules  are  critical
targets of oxidative damage; they contribute to respiratory uncoupling with increased ROS
production,  redox  stress,  and  a  cycle  of  senescence,  cytokine  production  and  impaired
oxidative phosphorylation. Targeting the formation or accumulation of oxidised biomolecules,
particularly oxidised lipids, in immune cells and mitochondria could be beneficial  for age-
related inflammation and comorbidities.
Recent Advances: Inflammation is central to age-related decline in health and exhibits a
complex relationship with mitochondrial redox state and metabolic function. Improvements in
mass  spectrometric  methods  have  led  to  the  identification  of  families  of  oxidised
phospholipids,  cholesterols  and  fatty  acids  that  increase  during  inflammation  and  which
modulate  Nrf2,  PPARγ,  AP1 and  NFkB  redox  sensitive  transcription  factor  activity.  The
kinetic and spatial resolution of the modified lipidome has profound and sometimes opposing
effects  on  inflammation,  promoting  initiation  at  high  concentration  and  resolution  at  low
concentration of oxidised phospholipid. 
Future  Directions: There  is  an  emerging  opportunity  to  prevent  or  delay  age-related
inflammation and vascular co-morbidity through a resolving (oxy)lipidome that is dependent
on improving mitochondrial quality control and restoring redox homeostasis. 
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Innovation:  (Per)oxidised  lipids  are  central  mediators  in  the  initiation  and  resolution  of
inflammation.  Generalised  targeting  of  lipid  peroxidation  with  antioxidants  such  as
tocopherols as a primary prevention in age-related, inflammatory vascular disease has not
proven  successful.  A  more  nuanced  view  is  emerging  where  ROS/NO  production  is
desirable during early phases of inflammation and for resolution. Indeed, the cell-targeted
amplification  of  ROS  in  neutrophils  may  be  required  during  inflammation  to  promote
resolution.  Phytochemicals  that  promote  resolving  oxylipid  mediators  and  improve
mitochondrial  quality  control  merit  further  investigation  as  inhibitors  of  underlying  sterile
inflammation and to mitigate age-related vascular disease. 
Key words: anti-inflammatory, oxidised phospholipids, oxysterols, metabolism,
eicosanoids, reactive oxygen species
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1. Introduction
Inflammation is an important physiological process that ensures homeostasis and survival.
But  as  we age,  inflammation  is  less  well-controlled  and may come at  a  cost.   Usually,
physiological  inflammation  is  triggered  by  non-self  materials  that  activate  surveillance
systems (complement and resident immune cells). The chemotactic mediators produced by
activated  complement  and  resident  cells  recruit  nicotinamide  adenine  dinucleotide
phosphate  oxidase  (NADPH)  oxidase  (NOX)-dependent  reactive  oxygen  species  (ROS)-
producing monocytes, macrophages and neutrophils to kill the invaders. This is followed by
lymphocyte recruitment and finally the switch-off  of  inflammation,  in a process known as
resolution. Figure 1 illustrates the key effector molecules and different cells involved during
the phases of physiological inflammation. Central to the control of physiological inflammation
is the metabolic inter-dependence of activation and resolution, and their redox sensitivities .
Mitochondria  are  central  to  inflammation and during ageing,  impaired  mitophagic  quality
control may promote low-level chronic inflammation with associated co-morbid diseases. 
This  review  considers  the  mechanistic  relationship  between  modified  lipids,  produced
enzymatically  and  by  free  radical  reactions  during  inflammation,  and  mitochondrial
metabolism, the inflammasome and the resolution phase of inflammation. We consider the
impact of ageing and age-related vascular diseases on lipid oxidation and mechanisms by
which  the  phytochemical  classes,  flavonoids  and  oxo-carotenoids,  may  mitigate
inflammation  by  preserving  mitochondrial  function  and  enhancing  nitric  oxide  (•NO)
availability.
2. Physiological inflammation and redox regulation
The initial lines of defence towards invading pathogens are non-specific circulating proteins
of the complement cascade combined with tissue resident cells of the innate immune system
such as macrophages and dendritic cells.  The complement cascade proteins will  release
chemotactic  fragments  following  contact  with  unexpected  molecular  pattern  molecules
(PAMPs) on pathogens . A well-known PAMP is bacterial lipopolysaccharide, LPS, that is
used widely  in  studies  of  inflammation.  LPS binds to Toll-like receptor  (TLR)4 triggering
endocytosis and NOX2 activation with associated production of superoxide anion radicals by
neutrophils  and  macrophages  .  The  tissue-resident  macrophages  are  present  in  low
numbers  throughout  the  body,  ready  to  perform a  random surveillance  role  and  initiate
physiological  inflammation.  To  achieve  rapid  deployment,  innate  immune  cell  activity  is
tightly coupled to differential use of substrates for energy and the metabolic phenotype .
While  inflammatory  macrophages  are  glycolytic,  rapidly  producing  ATP,  alternatively
activated  anti-inflammatory  macrophages  are  polarised  toward  mitochondrial  biogenesis,
oxidative phosphorylation and fatty acid oxidation .  The high degree of metabolic plasticity
of these cells enables them to mount a rapid response to infection and damage  and then
switch to resolution.
Intertwined metabolic pathways play a major role in immune function and inflammation. To
enable  switching  between  different  substrate  sources  according  to  inflammatory
environmental triggers, glucose, amino acid and fatty acid metabolism are coordinated by
the activity of redox sensitive transcription factors, nuclear factor erythroid 2-related factor 2
(Nrf2),  peroxisome proliferator-activated  receptor  gamma (PPARγ)  and  hypoxia-inducible
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factor 1-alpha (HIF1α) . It is lipid peroxidation products that are electrophilic activators of
these transcription factors. 
Oxidative damage to lipids, proteins and DNA is frequently observed during inflammation.
Extracellular oxidised lipids are ligands for TLR4, either directly activating receptor or acting
as  a  competitor  for  LPS  and  inhibiting  receptor  activation.  Mitochondrial  DNA  is  also
recognised  as  an  endogenous  damage-associated  molecular  pattern  (DAMP)  by  the
intracellular receptor, TLR9 . DAMPs also activate local resident innate macrophages, which
possess a series of pattern recognition receptors (PRRs) including TLR4 and nucleotide-
binding oligomerization domain (NOD)-like receptors (NLR) that are highly conserved , to
produce  chemotactic  cytokines  and  activate  the  nucleotide-binding  domain,  leucine-rich-
containing family, pyrin domain-containing-3 (NLRP3) inflammasome . In addition to being
activated by oxidised lipids, the NLRP3 inflammasome can also be activated by endogenous
metabolic  DAMPs including  many different  native  lipids;  fatty  acids,  ceramides and free
cholesterol .
The cells that respond most rapidly to infection and the emerging chemotactic gradients are
neutrophils  which phagocytose extracellular  pathogens, killing them via NADPH oxidase-
dependent ROS production within the phagosome . To increase their efficiency in pathogen
capture, neutrophils also produce neutrophil extracellular traps (NETs) from mitochondrial
DNA.  NADPH  oxidase -dependent  ROS  production  and  formation  of  NETS  are  also
essential  for the resolution of necrosis-induced inflammation  (Figure 2).  Neutrophil  nets,
together with proteins within the activated complement and the clotting cascades immobilise
pathogens and provide a physical barrier, preventing infection from spreading around the
body.  
While NADPH oxidase activation is essential for adequate NET production , ROS production
causes non-specific bystander oxidative damage. Neutrophils themselves will die rapidly due
to low antioxidant enzyme levels within 24 hours of recruitment; they are not equipped to
survive under conditions of oxidative stress and this is exacerbated with age . 
Monocytes  and  lymphocytes  appear  later  than  neutrophils  and  within  24  hours.  The
monocytes display a range of phenotypes and functions that are dependent on the local
environment; for example, if concentrations of DAMPS and pro-inflammatory cytokines are
high,  monocytes differentiate to macrophages and adopt an M1-type of pro-inflammatory
highly migratory phenotype to target infection to distant sites. This phenotype favours further
NADPH oxidase activation with superoxide anion radical production, expression and activity
of nitric oxide synthases (NOS) with associated nitric oxide production (although uncoupled
NOS which is more common during ageing increases peroxynitrite ONOO- production) as
reactive nitrogen species  (RNS)  and the production  of  inflammatory mediators.  M1 type
macrophages  depend  on  glycolysis  to  meet  the  metabolic  requirement  for  rapid  ATP
production (Figure 3). The pentose phosphate pathway is also upregulated under oxidative
stress and the presence of lipid peroxides in M1 macrophages via the Nrf2 pathway . This
increases availability of NADPH as an essential reducing agent to restore the antioxidant
glutathione  and redoxin  cycles.  In  an Nrf2  dependent  process,  the  antioxidant  enzymes
mitochondrial superoxide dismutase-2 (SOD2), glutathione reductase, thioredoxin reductase
and  peroxiredoxin  1  but  not  catalase  are  upregulated  in  macrophages,  enhancing  their
chance of survival during a high ROS environment . Neutrophils do not have this extent of
adaptation and antioxidant activity. Instead, after killing pathogens, neutrophils die, newly
recruited and resident macrophages sense the presence of apoptotic neutrophils via surface
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receptors such as CD36 and intercellular adhesion molecule 3, and then clear them in a
non-inflammatory  phagocytic  process  .  Local  tissue  macrophages  may  also  “cloak”  the
damaged site to prevent further neutrophil recruitment . 
Resolution of inflammation was once thought to be a passive process that simply ‘burns out’
with time, allowing for tissues to return to homeostasis. However, resolution of inflammation
is  now  recognised  as  an  active  programme  that  involves  sequential  synthesis  of  lipid
mediators  of  inflammation  (described  in  Section  3.3).  To  meet  the  demands  for
degradation  of  endocytosed  material  and  remodelling  the  extracellular  environment  to
promote  healing,  macrophages  adopt  mitochondrial-dependent  oxidative  phosphorylation
and secrete anti-inflammatory lipids formed by an enzyme-catalysed oxidation reaction from
the n-3 fatty acids and transforming growth factor beta (TGFβ), enabling the resolution of
normal physiological inflammation . The enzyme-catalysed oxidation of n-3 fatty acids leads
to  the formation of  protectins,  maresins  and resolvins  (D-  and E-series)  which normally
resolve acute inflammation and prevent chronic inflammation from developing. They affect
macrophage differentiation (explained in more detail in section 4 and  illustrated in Figure 5).
Interestingly, administration of resolvin D3 was also able to reduce joint inflammation in an
arthritis model,  suggesting that resolvins may also reverse and resolve chronic phase of
inflammation. D- and E-series resolving effects are not limited to the innate immune system;
they may also target recruited T and B cells at an inflammatory site.  In parallel, the recruited
lymphocytes (T cells normally) will recognise ROS-regulated, enzymatically-trimmed foreign
molecules that have been produced from a pathogen . Processed antigens are carried on
the surface of dendritic antigen presenting cells within a specialised protein, within the major
histocompatibility class, that enables the antigen to be recognised as foreign by T cells. T
cells in turn are activated, switch to glycolysis and promote the adaptive immune system to
produce  foreign-antigen  specific  antibodies  on future  contact  with  antigen  and enable  a
specific targeted immune response to be elicited . 
Dysregulation at each phase of inflammation may lead to a process that has been termed
sterile inflammation which becomes more common with age when there is no pathogenic
stimulus; non-resolution of inflammation is common during age-related co-morbidities.
3. Sterile inflammation and ageing
During ageing, the carefully orchestrated acute inflammatory response that enables effective
recognition of tissue damage and removal of pathogens is less well regulated. A process
described as “sterile” inflammation is frequently seen and is manifested in specific organs
and tissue e.g.  in the vasculature during atherosclerosis. Atherosclerosis is a maladaptive
phenotype  that  promotes  immune cell  recruitment  activation  and impairs  resolution,  can
accelerate ageing and age-related co-morbidities, and will be considered further. 
In  addition  to  the  production  of  ROS  by  NADPH  oxidase,  a  significant  increase  in
mitochondrial ROS production has been observed during ageing possibly due to ineffective
mitophagy . Some have reported that overproduction of mitochondrial ROS may increase
inflammation e.g. in atherosclerosis . Mitochondrial ROS generated by myeloid cells within
atherosclerotic plaques increase the concentration of the free-radical mediated cholesterol
oxidation  product,  7-ketocholesterol  (7-KC),  which is  the most  abundant  oxysterol  in low
density lipoprotein (LDL), and enhance the formation of atherogenic neutrophil NETs .  An
exaggerated “sterile” inflammatory response is generated to cholesterol-rich lipoproteins that
are retained in the arterial wall in the absence of any infection or tissue damage . Shirai et al
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have  identified  that  circulating  monocytes  from  atherosclerosis  patients  are  primed  to
produce  more  inflammatory  cytokines  via  mitochondrial  ROS-mediated  oxidation  of  the
glycolytic  enzyme pyruvate kinase M2 .   ROS play a role in regulating pro-inflammatory
priming of monocytes in response to oxidised lipids through epigenetic and metabolic re-
programming  e.g.  by  protein  acetylation  .  For  effective  priming  and  memory  of  an
inflammatory event, the acetylation of macrophage histone proteins is rate limiting according
to  the  availability  of  one  metabolite,  acetyl  CoA  (formed  in  abundance  by  during  lipid
metabolism), that is consumed by mitochondria. These observations highlight that lipids are
essential  sources  of  energy  and  are  increasingly  recognised  as  important  regulators  of
inflammatory signalling.
Histone  deacetylation  is  necessary  to  switch  macrophage  activity  towards  resolution  of
inflammation.  The associated modulation  of  gene expression is  closely  regulated by the
activity of sirtuin (SIRT) proteins and availability of the reducing agent nicotinamide adenine
dinucleotide (NADH); this again provides another link between inflammation and redox state,
as the availability of NADH is controlled by mitochondrial activity. Macrophage SIRT3 plays
an essential anti-inflammatory role through regulating mitochondrial bioenergetics and redox
homeostasis as well as controlling activation of the inflammatory protein complex, known as
the inflammasome  . The NLRP3 inflammasome has emerged as an immune sensor that
causally links systemic inflammation to ageing . It is responsible for the proteolytic activation
of the inflammatory cytokines IL-1β and IL-18 and mitochondria are involved; the NLRP3
inflammasome is  organised following activation at  the mitochondria  and this is achieved
through  its  binding  to  cardiolipin,  a  highly  abundant  phospholipid  in  mitochondrial
membranes . 
An  increase  of  ROS/RNS  production  by  immune  cells  is  observed  with  age  due  to
mitochondrial uncoupling and sterile inflammation and causes lipid peroxidation. There are
many classes of lipids that may be oxidised or nitrated. These include phospholipids and
cardiolipin,  sterols  and  fatty  acids.  Oxidised  cardiolipins  are  found  circulating  at  higher
concentrations during ageing  and are proinflammatory .  It  remains to be seen whether
oxidised  cardiolipin  accumulates  in  mitochondria  with  age  and  whether  this  influences
inflammasome activity. Mass spectrometry methods are now becoming sufficiently sensitive
to measure oxidised lipids in subcellular organelles to address this question.  
Over the following sections we review three principal classes of oxidised lipids; 1) oxidised
phospholipids, such as those formed by free radical oxidation of 1-palmitoyl-2-arachidonyl-
sn-glycero-3-phosphorylcholine  (PAPC),  that  have  been  shown  to  modulate  signalling
induced by bacterial lipopeptide or LPS, ; 2) oxysterols produced by free radical reactions or
enzymatically-produced  cholesterol  oxidation,  which  amongst  other  inflammatory  effects,
can regulate the activation of NLRP3 inflammasome by LPS ; and 3) the products of 12/15
lipoxygenase (12/15 LOX); specialised pro-resolving mediators e.g. lipoxins and resolvins,
acting  on G protein  coupled  receptors (GPCRs).  These lipid  (per)oxidation  products are
stable and can exert distant sites from their site of production. This raises the potential for
oxidised lipids to exert distant effects of ROS on inflammation in a time and concentration
dependent manner. 
We have previously described increased levels of lipid peroxidation products in the age-
related diseases rheumatoid arthritis, Alzheimer’s disease and cardiovascular disease  and
atherosclerosis  is  a  common  comorbidity  in  all  conditions.  Since  mitochondria  have  an
important role in proinflammatory signalling role during ageing  we consider in the following
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sections how a vicious cycle of lipid (per)oxidation may perpetuate mitochondrial dysfunction
and inflammation.
3.1  Peroxidised  phospholipids,  nitrated  fatty  acids,  inflammation  and  age-related
vascular disease 
A. Oxidised phospholipids (OxPLs)
Phospholipids  have structural  roles in  cell  membranes and while  maintaining membrane
integrity they may also function as second messengers . Phospholipids are substrates for
synthesis of lipid mediators including phosphoinositides, diacylglycerides, platelet-activating
factor, sphingosine-derived phospholipids, phosphatidic acids, and eicosanoids . 
Phospholipid  bound  polyunsaturated  fatty  acids  (PUFA)  such  as  arachidonic  acid  (AA),
docosahexaenoic acid (DHA) present in the second position of the glycerol  backbone of
phospholipids are also major targets for non-enzymatic oxidation by ROS/RNS to produce
the primary oxidation products, peroxyl radicals and hydroperoxides . Subsequent molecular
rearrangement, cyclisation or fragmentation and oxidation yield a diverse pool of oxidised
phospholipids  (OxPLs).  This  includes  full-length  or  shortened  carbon  chains  containing
oxygen functional groups such as hydroxy-, keto-, epoxy, hydroperoxyl- and prostane groups
as well as carboxylic and aldehydic terminal groups . In addition to being esterified within
phospholipids,  esterified oxidised PUFAs can also be detected as cholesterol  esters and
triglycerides. All exert distinct biological effects compared to their reduced parent molecules
in part due to increased polarity but also due to their chemical reactivity . The source of
oxidants predicts the likely subcellular  targets e.g. mitochondrial  DNA and cardiolipin are
readily oxidised when mitochondria become more uncoupled, and the nature of ROS/RNS
informs the chemistry of oxidation and the products that are formed. 
Several OxPL species may result from one individual precursor . For example, PAPC (the
major  phospholipid)  oxidation  results  in  oxygenated  full-length  products  e.g.
epoxyisoprostane (PEIPC) and epoxycyclopentenone (PECPC) as well  as fragmented or
truncated  products.  Truncated  PAPC  products  include  1-palmitoyl-2-(5-oxovaleroyl)-sn-
glycero-phosphatidylcholine  [POVPC]  and  1-palmitoyl-2-glutaroyl-sn-glycero-
phosphatidylcholine [PGPC] and have carbonyl groups that readily form adducts with other
biomolecules especially proteins . OxPLs can bind covalently to lysine, histidine, arginine
and cysteines via Schiff bases or as Michael adducts as well as to the amine groups of other
phospholipids.  Improvements  in  MS  methodologies  have  led  to  the  identification  of
membrane and cytosolic targets of proteins in cultured mouse macrophages that may be
modified by OxPLs; these included proteins involved with  apoptosis, stress response, lipid
metabolism and transport . 
Using model membranes, OxPLs with an aldehyde or a carboxyl group at their truncated sn-
2-chain end e.g. POVPC, PGPC were shown to be released rapidly, to be inflammatory and
to increase local membrane permeability whereas  oxygenated full-length products PEIPC
and PECPC were released more slowly and stabilised membranes . This led the authors to
suggest that early truncated oxidation products may promote vascular leakiness associated
with inflammation whereas the release of full length oxygenated products, perhaps as ROS
levels reduce during later phases of inflammation, may support resolution. In support of this
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hypothesis, the phospholipase catalysed release of 5,6-epoxyisoprostane that is present in
PEIPC has been shown to mimic the effects of pro-resolving prostanoids, through Michael
addition to essential Kelch Like ECH Associated Protein 1 (KEAP-1) thiols, facilitating Nrf2
activation.  Together  these  studies  illustrate  how  OxPL  are  involved  in  induction  and
resolution of inflammation .   
OxPLs present on oxidised lipoproteins, senescent and apoptotic cells are pattern associate
molecular  patterns  (PAMPs)  that  are  recognised  and  removed  by  soluble  and  cell-
associated PRR, including scavenger receptors such as CD36, natural (germ line-encoded)
antibodies, vascular endothelial growth factor receptors  on endothelial cells and C-reactive
protein  . Downstream  signalling  pathways  in  endothelial  and  mononuclear  cells include
receptor tyrosine kinase and MAP kinases,  that  signal  through intermediates to promote
inflammation by regulating  Activator  Protein 1 (AP1),  NF-κB, PPARγ and Nrf2 pathways
leading to the increased expression of cytokines and chemokines including TNFα, IL-1β, IL-
6, IL-8, MCP-1, MIP2, the lipid oxidation enzyme cyclooxygenase (COX)-2, and the homing
receptors CCR1, CCR2 and CCR5 . In endothelial cells, a high concentration of oxidised
PAPC was  shown  to  disrupt  barrier  function  due  to  increases  in  intracellular  ROS and
downstream activation of Src   that catalysed the phosphorylation of the adherens junction
protein vascular endothelial cadherin (VE-cadherin) at Tyr-731 and Tyr-658. This was not
observed  in  endothelial  cells  treated with low OxPAPC concentrations,  which conversely
showed potent barrier protective effects  .  Additionally, OxPCs with different chain lengths
also show opposite effects on barrier function where short chain OxPCs are reported to have
disruptive barrier function whilst long-chain OxPC induce protective barrier function . 
Elevated concentrations of fragmented OxPLs exert proinflammatory effects in monocytes
and  promote  foam cell  formation  but,  in  contrast  to  LPS,  do  not  activate  granulocytes.
Similar  to  the  effects  of  OxPL  on  endothelial  cells,  it  has  been  suggested  that
proinflammatory  effects  of  OxPLs  on  monocyte/macrophages  may  be  observed  more
frequently in sites of local to lipid accumulation sites . In contrast, at distant sites and with
lower concentrations, OxPL may be anti-inflammatory, possibly by competing with PAMPs
for  TLR4  binding.  Consistent  with  this,  it  has  also  been  shown  that  when  mouse
macrophages are treated with OxPLs, they undergo differentiation resulting in a phenotype
that  is  less  phagocytic  and  with  higher  Nrf2  activation.  However,  these  authors  also
fractionated  the  OxPLs  and  observed  that  truncated  species  of  OxPAPC  induced
reprogramming of macrophage metabolism (increased Glut1 expression, the major glucose
transporter)  to  support  antioxidant  gene  expression  (e.g.  haemoxygenase  1,  HO1;
thioredoxin reductase, TXRND1; and GCLM, glutamate cysteine ligase), while the full-length
OxPAPC treated macrophages showed increased expression of  cytokine and chemokine
e.g. IL-1β, IL-6 and CXCL1 genes encoding interleukin-1β, interleukin-6 and the chemokine
(C-X-C motif) ligand 1 .
The  increased  production  of  IL-1β by  OxPAPC-treated  monocyte  macrophages  and
endothelial cells indicates activation of the inflammasome by OxPAPC.  Again pleiotropic
effects of OxPAPC on inflammasome activation are described; it has been shown by some
authors  that  OxPAPC  binds  directly  to  caspase-4  and  caspase-11,  competes  with  LPS
binding, and consequently inhibits LPS-induced pyroptosis, IL-1β release and septic shock ,
whereas others have shown that POVPC injection resulted in the production of caspase-1,
IL-1β,  and  IL-18  in  wild-type,  but  not  in  NLRP3-deficient,  mice.  Furthermore,  POVPC-
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induced inflammasome activation  was  dependent  on  an  increase  in  mitochondrial  ROS;
ROS were increased following POVPC-mediated increases in intracellular Ca2+ signaling and
mitochondrial  destabilisation  ,  after  transient  POVPC  stimulation  of  transient  receptor
potential   channels  .  Collectively,  these  studies  illustrate  that  OxPL  are  effectors  of
bioenergetic  switch, mitochondrial  ROS production and altered redox state, potentially at
distant  sites,  and  their  local  concentrations  may  influence  whether  a  pro-  or  anti-
inflammatory phenotype predominates. 
B. Isoprostanes
Prostaglandin D2 and prostaglandin E2 GPCR receptors are important targets for prostanoid-
like products formed from OxPAPC and PEIPC, but not POVPC . Common stable products
of non-enzymatic free radical attack on phospholipids are isoprostane-like structures and
chain-shortened products containing carboxylic acid groups, carbonyl and hydroxyl groups.
These include arachidonic  acid-derived F2α-isoprostanes and other isoprostanes from α-
linolenic,  eicosapentaenoic  and  docosahexaenoic  such  as  F1-phytoprostanes,  F3-
isoprostanes and F4-neuroprostanes respectively .  F2α-isoprostanes regulate vasoactive,
mitogenic  and  inflammatory  properties  but  also  may  have  inhibitory  action  via  cAMP
signalling from the thromboxane A2 receptor (TBXA2R) on platelets .  Formation of  F2α-
isoprostanes is significantly increased in age-associated diseases such as obesity, diabetes
and atherosclerosis  .   F2α-isoprostanes may also compete with receptors to inhibit  drug
action – it has been suggested that aspirin-insensitivity in cardiovascular diseases may be
due to TBXA2 prostanoid receptor activation by F2α-isoprostanes .  The rearrangement of
F2α endoperoxide intermediates results in the formation of D2/E2-isoprostanes which can
undergo  further  rearrangements  generating  the  cyclopentenone  A/J-isoprostanes  .  In
contrast  to  the  inflammatory  effects  of  isoprostanes,  the  cyclopentenone  deoxy-A2/J2-
isoprostane-phosphocholines  15d-PGJ2  and  15d-PGJ2-PC,  formed  from  1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphocholine,  prevent  foam  cell  formation,  induce  anti-
inflammatory and anti-oxidant responses in macrophages through targeting redox sensitive
thiols within the NF-κB, PPARγ and Nrf2 pathways .  Some suggest that it  is  Nrf2 that is
largely responsible for the anti-inflammatory actions of oxidised lipids . 
Table 1 summarises the biological effects of OxPL and isoprostanes on inflammation and
atherosclerosis, illustrating both pro- and anti-inflammatory effects .  
C. Nitrated fatty acids
RNS derived from •NO, including ONOO-, nitrogen dioxide (•NO2) and nitrous oxide can also
oxidise and nitrate unsaturated fatty acids via the  homolytic addition of (•NO2) to a double
bond, to  form nitrated  lipids  .  In  addition,  •NO terminates  peroxyl  radical-induced  chain
propagation reactions of lipid peroxidation at a faster rate than tocopherol. Nitration specific
products from arachidonic, linoleic and oleic acids include nitroalkenes, nitro-nitrile esters,
nitrohydroxy species and β-nitroalkyl  radicals.  In addition, hydrogen abstraction may also
occur, producing similar fragmented peroxidation products to oxygen radical species attack .
Nitrated fatty acids were first described in 2003 and are considered to be protective in the
vasculature; they are the subject of several reviews . They have potent electrophilic activity,
forming adducts with proteins though Michael addition reactions . Their formation has been
reported in the plasma membrane, mitochondria, lipoproteins and triglycerides and they may
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be transported to distant sites within lipoproteins . Free nitro-fatty acids are found at very low
concentrations in the circulation,  probably  released by phospholipases .  They can target
extracellular receptors through nucleophilic attack and may be taken up in the esterified form
by  scavenger  receptors.  Intracellular  nitrated  fatty  acids  contribute  to  reversible  and
exchangeable nitrated fatty acid-thiol  adducts occur under biological  conditions  and are
effective inhibitors of NF-kB; alkylation of macrophage p65 by nitroalkene fatty acids inhibits
NF-kB DNA binding activity and represses downstream inflammatory target gene expression
. Nitrolipids are also potent agonists of PPARγ and Nrf2, binding to thiol  on KEAP1 and
releasing  Nrf2  which  directs  antioxidant  and  anti-inflammatory  and  metabolic  gene
expression in monocytes/macrophages and endothelial cells. There are intrinsically different
potencies of regioisomers of nitro fatty acids . In contrast to ROS-inducing activity of OxPLs,
nitrolipids have been reported to inhibit  activation of the NADPH oxidase via nucleophilic
attack on thiol residues in p47 Phox , possibly involving the formation of a covalent Michael
adduct  between  NO2-AA  and  critical  nucleophilic  residues  (e.g. histidines  or  cysteines)
preventing  the formation of  the active complex.  Within mitochondria,  mild  uncoupling  by
nitrolipids  has  been  described  which  in  turn  promoted  adaptation  during  ischemia  and
reperfusion,  a  sterile  inflammatory  response  involving  production  of  ROS ,  and
cardioprotection. 
To date there are no reports describing any change of nitrolipids with age, however, it is
known that endothelial NOS efficiency decreases with age due to uncoupling , potentially
reducing the rate of anti-inflammatory nitro-lipid formation and increasing ONOO --mediated
lipid peroxidation. Furthermore, our previous study has shown that the median concentration
of  plasma  linoleic  acid  is  reduced  by  50%  in  healthy  adults  over  50  years,  reducing
availability of a major substrate for nitration by  •NO  . The in situ generation of nitrolipids
within  mitochondria  highlights  their  significant  role  for  coordinating  the  regulation  of
metabolism  and  inflammation,  driving  an  anti-inflammatory  phenotype  ,  and  efforts  to
increase eNOS coupling may contribute to anti-inflammatory activity via nitrolipid formation
to mitigate risk and severity of inflammageing and atherosclerosis. 
3.2 Oxysterols, inflammation and age-related vascular disease
ROS oxidise the unsaturated rings of cholesterol yielding several oxysterols that differ in the
position  of  hydroxyl  group addition.  In  addition  to free radical  mediated oxidation,  some
oxysterols  are  formed  by  specific  enzymatic  oxidation  reactions  to  produce  short-lived
intermediates that are involved in cholesterol excretion pathways; they may also be taken up
in the diet (Figure 4). Compared to highly abundant cholesterol that circulates in blood at
millimolar  levels,  oxysterols  are  reported  to  found  in  1,000-10,000  times  lower
concentrations around micromolar to submicromolar  levels in human plasma . Regardless
of the source or the concentration, oxysterols are taken up by a range of receptors (LDL
receptors,  EBI1;  Epstein-Barr-virus-induced G-protein coupled receptor 2,  also known as
GPR183),  scavenger  receptors,  G-protein  coupled  receptor  17  (GPRI7),  C-X-C  Motif
Chemokine  Receptor  2  (CXCR2),  glucocorticoid  receptor,  purinergic  (P2X7)  receptor,
Smoothened, Frizzled Class Receptor (SMO),  Glutamate Ionotropic Receptor NMDA Type
(NMDA),  NPC Intracellular  Cholesterol  Transporter  1 (NPC1;  see Figure 4)  and exert  a
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range  of  biological  effects.  At  high  concentrations,  oxysterols  are  cytotoxic  and  pro-
atherogenic compared to cholesterol, especially in vascular cells. 
Similar to other oxidised lipids, addition of a hydroxyl,  epoxide, hydroperoxyl, carboxyl or
ketone  moieties  to  the  steroid  nucleus  or  to  the  side  chain,  increases  the  polarity  of
oxysterols . To date, the subcellular distribution of oxysterols has not been characterised,
although increased concentrations are predicted to occur  in  mitochondria during ageing,
which may influence cellular metabolism. In membranes, a change in behaviour in micro
environments by oxysterols has been shown to affect membrane fluidity , cell signalling and
metabolism .  Oxysterols  are  stable  species  that  are  found  within  lipoproteins  or  free in
serum; they can diffuse within LDL to distant sites, may cross the blood brain barrier  and
are taken up by discrete receptors to influence cell cholesterol and mitochondrial metabolism
(Figure 4). 
Enzymatically  produced oxysterols  have been studied in  relation  to  health  and vascular
diseases. The cytochrome P450 family gene,  CYP27A1, encodes a mitochondrial enzyme
which catalyses the formation of 27-hydroxycholesterol (27-OHC) and modulates the acidic
biosynthetic pathway for bile acids. 27-OHC is the most prevalent enzymatically produced
oxysterol in human circulation ranging from 150- 730 nM but increases more than two fold in
atherosclerotic  lesions  .  As  competitors  for  binding  estrogen  receptor  α,  atherogenic
properties  of  27-OHC  have  been  attributed  to  the  attenuation  of  estrogen-related
atheroprotection  .  Additionally,  27-OHC induces adverse effects  in  the brain  by passing
through the blood-brain-barrier  and interrupts local cholesterol homeostasis .
We have shown previously that 27-OHC alters the distribution of membrane microdomains in
neuron-like cells to increase the activity of beta secretase to produce amyloid beta  in vitro.
In neurones,  cholesterol  is  converted into 24S-hydroxycholesterol  (24-OHC).  Excess 24-
OHC crosses the blood-brain-barrier  to reach the blood and is metabolised by the liver,
converted into biliary acids and eliminated into the bile. Both 24-OHC and 27-OHC increase
proportionally to the number of e4 alleles in individuals with cognitive decline and a positive
correlation has been reported for APOE genotype and 24-OHC levels in cerebrospinal fluid
from patients with Alzheimer’s disease and mild cognitive impairment . Another prospective
ageing study reported that lower cholesterol present in ApoE epsilon 4 carriers was related
to a higher rate of decline of information processing speed and a higher ratio of 27-OHC to
cholesterol was related to a lower level of general performance and memory functioning. The
authors concluded that lower total cholesterol and high oxysterol levels may be considered
as a frailty marker, predictive of lower cognitive functioning in the elderly . 
Both 27-OHC and 25-hydroxycholesterol (25-OHC) regulate immune cell function. 25-OHC
is synthesised by the enzyme cholesterol 25-hydroxylase. Initial studies by Park and Scott
revealed that 25-hydroxylase gene expression is low in resting macrophages under standard
cell  culture conditions but is rapidly  induced by two orders of  magnitude when cells are
activated  with  TLR ligands  .  Other  oxysterols,  7α-OHC and  7α,  25-dihydroxycholesterol
(7α,25-OHC)  are  reported  as  a  high-affinity  ligands  for  the  inflammatory  receptor  EBI2/
GPR183 that is induced in B cells upon viral infection .
In  addition to a direct  antiviral  role,  25-OHC also  regulates  transcription of  inflammatory
genes.  25-OHC amplified the TLR-induced gene expression through a positive feedback
response mediated, at least in part, via the transcription factor, AP1 . The induction of pro-
inflammatory cytokines by 25-OHC is also dependent on increased NFκB activation, most
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likely following the activation of p38 MAPK and JNK . Umetani et al reported the activation of
endothelial and macrophage NFκB pathway by 27-OHC . Peritoneal macrophages from 27-
OHC treated mice upregulated mRNA level of TNF-α, IL-1β and IL-6 by 3 to 6 fold and
promoted  monocyte-endothelial  cell  adhesion  through  estrogen  receptor  (ER)-α  driven
pathway .  Several  closely  related sterol  regulatory  transcription  factors are regulated by
oxysterols including LXR, RXR, RORα,  RORβ, RORγ,  ERα. Some oxysterols are able to
induce metabolic  reprogramming upon uptake;  they are involved in  polarising  M1 to M2
macrophages through the LXR transcription factor . In this process, the oxysterol activated
LXR pathway drives macrophages to recognise dead cells, promotes cholesterol efflux and
down regulates inflammatory gene expression, further illustrating the relationship between
oxidised lipids, metabolism and inflammation.
Anti-inflammatory properties of oxysterols have also been reported; Vurusaner et al have
shown  that  low  micromolar  concentrations  of  27-OHC  can  activate  the  redox  sensitive
transcription factor, Nrf2 and subsequently the target genes, HO1 and NQO1 in monocyte-
like cell  line,  U937 . Early and transient generation of ROS levels by 27-OHC enhanced
MEK-ERK/PI3K-Akt phosphorylation, which in turn reduced the subsequent ROS production
suggesting the ability  of oxysterols as pro-survival  inducers at low concentration . In the
same  cell  line,  27-OHC  activated  an  autophagic  response  by  expressing  upregulated
microtubule-associated protein 1A/1B-light chain 3 (LC3) II/LC3 I ratio and Beclin 1 levels in
a MEK-ERK/PI3K-Akt dependent manner . 
To  study  the  short  term  effect  of  free  radical  mediated  cholesterol  oxidation  products
acquired  from  the  diet,  Vine  et  al  analysed  non-enzymatically  produced  7β-
hydroxycholesterol (7β-OHC), 7- KC and 5α,6α-epoxycholesterol after two weeks of feeding
rabbits with chow supplemented with oxidised cholesterol (containing 6% oxysterols) . The
authors did not observe any changes to 7β-OHC levels but five times higher levels of 5α,6α-
epoxycholesterol and double the levels of 7-KC were found in triglyceride-rich lipoproteins
from oxidised cholesterol-fed animals compared to the purified cholesterol-fed animals. The
oxidised cholesterol-fed animals also had a 64% increase in total aortic cholesterol. This is
consistent with the observation that 7α-OHC, 7β-OHC and 7-KC are found in relatively high
concentration in foam cells and fatty streaks .  Foam cells are formed after oxidised lipid
loading into recruited macrophages; and it is estimated that oxysterols comprise up to 50%
of  total  sterol  content  of  OxLDL-loaded  cells  .  The  underpinning  mechanism  of  plaque
formation is likely to be via 7-KC enhanced leukocyte-endothelial interactions . In an attempt
to  prevent  foam  cell  formation,  macrophage  lysosomal  lipase  hydrolyses  the  ingested
cholesteryl  esters.  In concert,  25-OHC is  synthesised,  probably  in  mitochondria  where it
maintains  membrane  integrity,  and  prevents  mitochondrial  ROS production  and  NLRP3
inflammasome  activation.  Lysosomal  lipase  activity  is  also  required  for  LXR-mediated
activation of cholesterol efflux (Figure 4) ; free intracellular cholesterol is transported to the
mitochondria via steroidogenic acute regulatory protein where CYP27H catalyses oxysterol
synthesis. 27-OHC is a regulatory oxysterol that not only activates LXR and mediates lipid
efflux, but also modulates PPARγ activity and suppresses IL-6, TNFα and IL-1β production
by macrophages . This evidence supports an important role for oxysterols in regulation of
inflammation via the mitochondrion. 
In  summary  there  is  accumulating  evidence  for  a  role  of  oxysterols  in  regulating
inflammation. The biological effects may be pro- or anti-inflammatory according to oxysterol
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concentration.  However,  whether  they  undergo  covalent  interactions  or  act  as  partial
agonists/antagonists remains to be determined. 
3.3 Eicosanoids, inflammation and age-related vascular disease
The  eicosanoids  are  another  group  of  oxidised  lipids  that  integrate  with  metabolism,
regulating both the initiation and resolution of inflammation (Figure 5). The immune system
sentinels,  neutrophils  and  monocytes/macrophages,  require  a  directional  signal  both  to
migrate to the site  of  tissue injury,  during the acute inflammation phase,  and back out,
removing  cellular  debris  and  clearing  out  invading  pathogens  without  tissue  injury.  The
cardinal ‘signals’ come in the form of chemoattractant bioactive lipids that are produced by
the  coordinated  action  of  receptors,  phospholipases  and  oxygenases.  Thus,  they  are
considered to play  key roles  driving  both pro-inflammatory and pro-resolving responses.
While they are also electrophilic in nature and are formed through enzyme-controlled free
radical reactions, the biological effects are not mediated through covalent modification of
targets but rather as conventional ligands for receptors and transcription factors. 
Pro-inflammatory lipid mediators are produced and released by the host cells with an aim to
create  chemotactic  gradient  that  will  support  transendothelial  migration  of  professional
phagocytes  to  the  site  of  injury.  They  include  eicosanoids,  namely  leukotrienes  (Lts),
prostaglandins  (PGs)  and  thromboxanes  (TXs),  Figure  6.  These  lipid  mediators  are
synthesised  from  membrane-derived  AA  within  minutes  of  an  acute  challenge.
Phospholipase A2 (PLA2) hydrolyses phospholipids at the sn2 position to generate fatty acid
substrates for oxidation by cyclooxygenases (COX) and lipoxygenases (LOX).
Production of leukotrienes from free AA is initiated by the enzyme 5-lipoxygenase (5-LOX).
The most  potent  of  all,  leukotriene B4 (LtB4)  is  produced mainly  by neutrophils  and pro-
inflammatory macrophages. By ligating to G-protein coupled receptor BLT1/2, LtB4 supports
further recruitment and activation of circulating leukocytes to the site of cellular injury.  
Metabolism  of  AA  by  cyclooxygenase  (COX)  and  thromboxane  synthase  leads  to  the
formation of  thromboxanes. Thromboxane A2 (TXA2), mainly produced by monocytes and
macrophages,  exerts  its  pro-inflammatory  actions  through  binding  to  the  thromboxane
receptors TP that belong to the family of G-protein coupled receptors. Thromboxane is best
known for being a potent platelet aggregant and vasoconstrictor. 
The prostaglandin profile in tissues depends on the activity of COX-1 and COX-2, enzymes
with  both  cyclooxygenase  and  peroxidase  activity.  During  homeostasis  COX-1  is  the
dominant catalyst in formation of prostaglandins. Upon receiving an inflammatory stimulus,
the expression of COX-2 becomes upregulated, leading to the synthesis of pro-inflammatory
prostaglandin E2 (PGE2), prostaglandin D2 (PGD2) and prostaglandin F2α (PGF2α). Hence, the
prostaglandin profile is dependent on both the levels of expression of enzymes responsible
for  their  synthesis  and the cell  activation  state.  Indeed,  TXA2 is  produce by  the resting
macrophages, while the synthesis of PGE2 is favoured upon cellular activation. 
The actions of PGF2α, are mediated by its individual receptors FP, PGD2 and PGE2 activate
multiple  receptors  that  are  differentially  expressed  in  immune  cells,  thereby  triggering
immune  responses.  In  the  context  of  this  review,  the  most  important  cellular  response
mediated by PGE2 and PGD2 is the lipid mediator “class switch”. While both known for their
pro-inflammatory activities, PGE2 and PGD2 each promote a switch in the upregulation of
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key enzymes to promote synthesis of dual-acting specialised pro-resolving lipid mediators of
inflammation (SPM).
The dual-acting nature of SPM is reflected in their ability to selectively stop further infiltration
of neutrophils to the site of acute challenge while supporting pro-resolving futures, such as
recruitment  and  activation  of  monocytes  without  pro-inflammatory  stimuli  (non-phlogistic
stimulation),  phagocytosis  of  apoptotic  cells  and microorganisms,  exit  of  phagocytes  via
lymphatics and upregulation of antimicrobial agents. 
Lipoxins, namely lipoxin A4 (LxA4) and lipoxin B4 (LxB4), are the first SPM to be recognised
for their dual-acting nature. They are derived from AA in a form of trihydroxy derivatives via
two  different  routes.  For  example,  in  mucosal  tissue,  lipoxins  are  released  due  to  the
interactions between leukocytes and epithelial cells. Here, synthesis of lipoxins is initiated in
epithelial  cells  by the 15-lipoxygenase (15-LOX), leading to the formation of 15-hydroxy-
eicosatetraenoic acid (15-HETE) intermediate. This substrate is provided to neutrophils for
the final synthesis of lipoxins by 5-LOX. In blood vessels lipoxin synthesis is ensured by an
interplay  between leukocytes  and platelets.  Leukocyte-derived 5-LOX metabolises  AA to
form epoxide intermediate LtA4. Studies have shown that more than 50% of LtA4 is further
metabolised by platelet 12-lipoxygenase (12-LOX) to produce lipoxins. In macrophages, a
unique two-step activation mechanism ensures controlled production of  lipoxins; first TLR4
activation  results  in  accumulation  of  an  esterified  form  of  the  COX-2-derived  lipoxin
precursor 15-HETE which is stored within membrane phospholipids. Subsequent activation
of P2X7 by extracellular ATP leads to phospholipase A2 activation, hydrolysis of 15-HETE
from membranes and its conversion to lipoxins by 5-LOX, linking inflammasome activation to
resolution . LxA4 binds to lipoxin A4 receptor (ALX) on leukocytes thereby triggering cell-
specific responses. In neutrophils, this interaction will stop neutrophil chemotaxis, adherence
and transmigration into the inflamed sites, while in monocytes it stimulates chemotaxis and
non-phlogistic responses. LxA4-ALX interaction in T cells blocks secretion of TNFα providing
the link between the innate and adaptive immune systems .  
E-series resolvins, namely resolvin E1 (ResE1) and resolvin E2 (ResE2), are derived from
18-hydroxy-eicosapentaenoic acid (18-HEPE) via two pathways. EPA can be converted into
its hydroxy derivative in the presence of aspirin or by the cytochrome P450 enzymes, which
can  be  transformed by  5-LOX in  leukocytes  (mainly  neutrophils)  to  ResE1  and  ResE2.
ResE1  exerts  its  dual-action  nature  by  interacting  with  at  least  two  G  protein  coupled
receptors.  Interaction  with BLT1 on neutrophils  prevents transendothelial  migration while
interaction  with  chemokine-like  receptor  1  on  monocytes  supports  non-phlogistic
phagocytosis of apoptotic leukocytes. In peripheral blood leukocytes, ResE1 prevents the
decrease  in  mitochondrial  respiration,  membrane  potential,  and  the  imbalance  of
mitochondrial fission and fusion that is induced by TNFα; since mitochondrial fission alone
can induced proinflammatory cytokines, a novel anti-inflammatory mechanism of ResE1 may
be through maintenance of mitochondrial integrity . 
Docosahexaenoic  acid (DHA) is  a  PUFA  that  is  highly  enriched  in  brain,  retina  and
synapses. Hence, D-series resolvins (ResD1-D4) derived from DHA via metabolism by 15-
LOX/5-LOX are of a great importance as ‘guards’ of neural tissues. It is important to note
that synthesis of  D-series resolvins can be also triggered with aspirin.  In microglia,  both
ResD1 and its aspirin analogue indirectly block synthesis of pro-inflammatory interleukin-1β,
which  is  rapidly  released  following  brain  injury.  They  also  protect  macrophages  from
efferocytosis-induced death via ResD1 mediated activation of cAMP-PKA signaling, which in
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turn  inhibits  p47  phox  phosphorylation,  suppressing  NOX activation  and  limiting  further
oxidative damage .  In the liver  during ischemia reperfusion, ResD1 regulates mitophagy,
mitochondrial  biogenesis  and  mitochondrial  fission  via  thioredoxin  2,  and  reduces
mitochondrial  oxidative stress .  In another elegant  study in macrophages,  the binding of
ResD2 to the GPR18 receptor was shown not only to inhibit the priming but also to expedite
the deactivation of  the NLRP3 inflammasome during the resolution process,  probably by
preventing apoptosis-associated speck-like protein oligomerisation at the mitochondria and
inflammasome assembly .
Protectins represent  another  class  of  bioactive  lipid  mediators  produced from DHA via
lipoxygenase pathway, with protectin D1 (PD1) being the most potent. They are produced by
neutrophils, macrophages, T cells, glial cells and retinal pigment epithelium. Although it is
known that they can bind leukocytes and retinal pigment epithelium cells, the exact binding
partner  is  yet  to  be  determined.  PD1  upregulates  CCR5  expression  in  neutrophils  and
stimulates  non-phlogistic  uptake  of  apoptotic  leukocytes  by  macrophages.  Maresins
represent the third class of SPM derived from DHA via metabolism by 12-LOX/5-LOX. The
exact receptors for maresins remain unknown. However there is an evidence that maresins
limit  neutrophil  transendothelial  migration,  promote  uptake  of  apoptotic  leukocytes  by
macrophages, and shorten the resolution phase.  
During ageing, inflammageing is associated with lower SPM concentration . Lower maresin,
ResD and ResE concentrations during ageing associate with poor cardiovascular outcomes .
Lower  SPM  concentration  effects  on  heart  function  relate  to  a  combination  of  altered
metabolism and increased dietary intake of n-6 fatty acids that correlate with inflammation
and oxidative stress . In support, delivery of resolvins in nanoparticles can reverse a decline
in cardiac function in animal models by promoting efferocytosis and phenotype switching
[145]. In a balloon model of vascular injury, both ResD1 and D2 inhibit  vascular smooth
muscle  activation,  monocyte  recruitment  and  ROS  production   and  ResD2  promotes
revascularisation post-ischemia via GPR18 receptor dependent mechanisms . In the brain,
histological post-mortem brain studies from people with cognitive impairment but not healthy
people have also shown increased levels of the cyclooxygenase, COX-2, greater oxidative
damage and more oxidised lipid deposition . Furthermore,  the eicosanoid precursors DHA
and AA,  are  significantly  dysregulated  in  the  brains  of  patients  with  varying  degrees of
Alzheimer pathology . Therapeutic activation the resolution pathways has great potential for
the treatment of inflammatory diseases. Could appropriate nutrition be a link between innate
and adaptive immune system? Studies with n-3 PUFAs supplementation for inflammatory
resolution and neuroinflammation have not shown consistent outcomes  .  It is known that
older adults lack delta-6-desaturase (D6D) activity when compared to younger adults  which
is required for conversion of fatty acids to n-3 PUFAs. In the absence of  D6D, AA may
predominate as a proinflammatory substrate for COX-2. Furthermore, before tissue-specific
treatments become available, it is important to address whether dietary supplementation with
PUFA or SPM intermediates can be beneficial for the local production of SPM, or if their
supplementation in excess may have deleterious effects due to the increased risk for auto-
oxidation.  Instead,  novel  approaches that  address mitochondrial  quality  may prevent  the
activation of the inflammasome , generation of high concentrations of oxidised lipids and
enable  macrophage  differentiation  to  a  resolving  M2  phenotype  and  yielding  anti-
inflammatory outcomes. 
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This review is focussed on involvement of oxylipins in inflammation and its resolution with
relation to age-related vascular  disease.  The vasculature itself  is  exposed to a range of
oxygen tension, but the variance is less than in other tissues. It is worthy of note that some
studies  that  have  explored  oxylipins  under  physiological  conditions  of  extreme  oxygen
tension, for example in the lung (higher oxygen tension) or exercising muscle (hypoxia). The
free-radical  dependent  formation  of  oxidised  phospholipids  and  fatty  acids  is  increased
during hyperoxia and during reperfusion post-ischemia, however, their biological effects in
lung and muscle are similar to those reported in the vasculature with both pro- and anti-
inflammatory effects  being  described . Nevertheless,  there  is  a consistent  view that  the
enzyme catalysed eicosanoids play an important role in the regulation of inflammation and
may be targeted to improve muscle regeneration .
3.4 Analytical challenges of measuring products of lipid oxidation
The foregoing discussion has highlighted that oxidised lipids generated from PUFA, 
cholesterol and phospholipids through enzymatic or free radical mediated reactions are 
structurally similar, with similar chemical and physical properties. These properties make it 
difficult to simultaneously separate, and accurately identify and quantify oxidised lipids in 
biological samples . Since the regulation of different lipid oxidation species may shift the 
balance between inflammatory and anti-inflammatory status, and because these processes 
are fine-tuned, accurate and precise quantitation are important. It is also noteworthy that 
most of the oxidised lipids are unstable compounds that can degrade or further oxidise 
during sample collection, handling and storage. Therefore, special care and attention is 
needed starting from the point of experimental design. These challenges have been 
reviewed by others , which emphasise the need of standardised approaches to sample 
preparation lipid extraction and storing lipid oxidation products. For example, removal of 
highly abundant parent lipids (cholesterol, phospholipids) and concentration of oxidised 
species are required to avoid interference and to optimise detection limits. Techniques such 
as sample evaporation, liquid-liquid extraction and solid phase extraction have been 
reported in literature. Each of these techniques has their limitations on sample recovery and 
extraction efficiencies . Advances in analytical techniques, availability of high sensitive 
instruments and column chemistries are playing a major role in overcoming these challenges
. However, still the complex nature of lipid species and their interaction with solid phase 
matrix in different strengths may pose challenges to extract all species with a same 
efficiency .
In recent years, much effort has been invested to accurately quantify lipid oxidation products 
from minimum sample volumes .  The development of ultra-high performance liquid 
chromatography methods with short runtimes using targeted and sensitive quantification 
using quadrapole ion trap mass spectrometers has been successfully applied to different 
types of biological samples  and is likely to revolutionise our understanding of the spatial and
temporal distribution of these modified lipids. 
4. Flavonoids mitigating lipid oxidation, inflammation and age-associated vascular
disease 
Two  classes  of  phytochemicals  that  are  less-well  studied  but  have  positive  age-related
health outcomes are the oxocarotenoids and flavonoids. Oxocarotenoids are metabolised by
mitochondria, promote membrane integrity and vascular risk factors. On the other hand, in
the PREDIMED study the increase in circulating flavonoids were associated with preventing
negative  cardiovascular  outcomes  in  older  adults  following  dietary  supplementation  with
olive oil  and with or without  nuts, and for type diabetes, catechins, proanthocyanins and
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hydroxybenzoic acid afforded the greater protection .  The next two sections focus on the
mechanisms and effects of these phytochemicals on oxidised lipids; despite being under-
investigated in  clinical  studies,  they show promise to exert  anti-inflammatory effects and
protect against age-related vascular disease. 
Diet is a major determinant of healthy aging and the flavonoid phytonutrients may extend
healthy lifespan and prevent age-related vascular mortality . This hypothesis is based on
human  epidemiological  and  clinical  intervention  studies  and  lifespan  studies  in  model
species. The mechanisms are not fully understood and include modulation of nitric oxide-
dependent  arterial  function   regulation  of  NADPH  oxidase,   immune  and  inflammatory
function modulation via Nrf2 activity modulation of the inflammasome,  CNS/neuronal cell
function modulation . Pre-clinical studies in mice have shown that flavonoids may attenuate
inflammation  through  inhibition  of  the  inflammasome  and  promoting  mitochondrial
biogenesis  is  also  enhanced  in  many  tissues  . Mitochondrial  biogenesis  increases  the
efficiency  of  mitochondrial  metabolism  and  promotes  differentiation  to  anti-inflammatory
phenotype.
Flavonoids  are  the  biggest  group  of  polyphenolic  secondary  plant  metabolites  found  in
human  diets  .  Major  classes  of  flavonoids  are  flavan-3-ol  monomers,  theaflavins,
proanthocyanidins, anthocyanidins, flavones, flavonols, and flavanones - they differ in their
abundance  in  foods,  absorption,  metabolism,  distribution,  and  excretion  .  An  important
reason for the lack of clarity of molecular targets and mechanisms is the likely importance of
considering the absorption,  distribution,  metabolism,  and excretion (ADME) of  flavonoids
when  investigating  their  mechanisms;  this  was  previously  underappreciated  .  Most
flavonoids undergo significant metabolism during absorption and therefore, the circulating
metabolites significantly differ from the flavonoids in food. For instance, flavanols in cocoa
consist  of  monomers,  mainly  (-)-epicatechin  (20%)  and  procyanidins  (80%)  which  are
oligomers with a degree of polymerisation of up to 10 monomers. However, recent research
has  shown  that  (-)-epicatechin  is  methylated,  sulphated  and  glucuronidated  during
absorption in the small intestine while procyanidins are not absorbed as such and are broken
down by the gut microflora, reaching the circulation much later e.g. as valerolactones . While
studies  in  the  past  have  shown  that  many  polyphenols  including  (-)-epicatechin  and
procyanidins can mediate a number of effects in vitro including inhibition of NADPH oxidase
with the half maximal inhibitory concentration (IC50) values in the micromolar range, these
are seldomly reached in vivo limiting the understanding of  how flavanols  mediate health
benefits  in  humans  in  vivo  .  More  recent  work  with  structurally  related  (-)-epicatechin
metabolites  at  physiologically  relevant  concentrations  in  human  endothelial  cells  using
systems  biology-based  network  analysis  suggests  that  epicatechin  metabolites  trigger
complex nutri(epi)genomic changes that subsequently  modulate endothelial  cell  adhesion
function and permeability.  This study also identified key molecular and cellular  targets of
epicatechin associated with their vascular protective effects  in vivo . Flavanol metabolites
reduce monocyte adhesion to endothelial cells through modulation of expression of genes
via p38-MAPK and p65-NF-kB pathways . Whether there is any effect on concentration of
(per)oxidised lipids is unknown. Comparison of the 253 differentially expressed genes with
the 4787 TNFα-modulated genes revealed an overlap of  66 genes.  Interestingly,  among
these 66 common genes, 44 presented opposing gene expression profiles, suggesting that
epicatechin metabolites could partially counteract the genomic effect induced by TNFα in
endothelial  cells.  Another  interesting  class  of  flavonoids  are  anthocyanins  which  give
blueberries their blue colour. While the parent compounds are not likely to be absorbed in
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relevant  amounts,  there  are  many  smaller  phenolic  degradation  products  that  reach
micromolar  plasma  concentrations  and  may  lead  to  significant  health  effects  .  Ex  vivo
experiments  showed  that  anthocyanins  and  their  gut  metabolites  can  affect  adenosine
diphosphate-induced  platelet  activation  and  their  aggregation  with  monocytes  and
neutrophils   and  attenuate  monocyte  adhesion  and  transendothelial  migration  through
nutrigenomic mechanisms regulating endothelial cell permeability .
Human  flavonoid  intake  varies  considerably,  and  epidemiological  data  rely  on  food
frequency questionnaires. Based on food consumption data from the European Food Safety
Authority and the FLAVIOLA Food Composition Database, it was estimated that in Europe
the mean daily intake is 430 mg/d and the median id 160 mg/d with tea and fruit being the
main source . Data from anthropological research  and observational studies  suggested that
flavonoids can reduce the risk of ageing-related pathologies such as cardiovascular disease
although results from more recent studies were less clear  and the main beneficial effect
emerges when comparing  very  low intake with  low intake.  Overall,  a  systematic  review
suggests  that  the  dietary  intakes  of  six  classes  of  flavonoids,  namely  flavonols,
anthocyanidins,  proanthocyanidins,  flavones,  flavanones  and  flavan-3-ols,  significantly
decrease  the  risk  of  CVD  .  Unfortunately,  randomised  controlled  or  prospective  trials
studying human morbidity  or  mortality  as  an endpoint  for  flavonoid  supplementation  are
scarce with the exception of the ongoing COSMOS trial .
Putative  mechanisms that  may underlie  flavonoid  benefit  as  identified  in  worms include
energy-restriction-like effects, inhibition of insulin-like-growth factor signalling,  induction of
antioxidant  defence  mechanisms,  lowered  inflammation,  hormesis,  and  antimicrobial
properties.  Lifespan  studies  show  that  flavonoids  can  promote  longevity  in  a  range  of
species  .  In  most  studies,  worms  and  flies  experienced  lifespan  extension  when
supplemented with flavonoids either as extracts or single compounds. Studies with mutant
worms and flies give hints as to which gene products may be regulated by flavonoids and
consequently  enhance  longevity.  Although  flavonoids  can  work  as  radical  scavengers
because of their chemical structure; their in vivo antioxidative action is more likely caused by
them stabilising and up-regulating the antioxidant transcription factor Nrf2. Interestingly, in
flies, cocoa powder was tested in SOD-deficient mutants and it prolonged life-span in flies
that did not have the cytosolic SOD1 but was detrimental for flies without the mitochondrial
SOD2. These findings suggest that when oxidative stress levels are very high, flavonoids
could  further  increase  oxidative  damage  .  The  metabolome  of  flavonoids  differs  widely
between mice and men making comparative conclusions difficult , and studies in mice are
not discussed further here. Readers are directed to a few studies in mice .
Taken together,  while  flavonoids are promising phytonutrients that may extend a healthy
lifespan and limit  vascular co-morbidities, this remains to be demonstrated clinically.  The
underlying  mechanisms  of  individual  flavonoids  and  their  circulating  putatively  bioactive
metabolites and their interactions with inflammatory pathways remain to be elucidated taking
their ADME into account.
5. Carotenoids, inflammation and age-related dementia and vascular disease
PUFA are highly susceptible to peroxidation.  Carotenoids can quench singlet oxygen and
scavenge lipid peroxides .   They are defined into  two groups according to their polarity:
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xanthophylls (polar carotenoids such as astaxanthin, β-cryptoxanthin, lutein, and zeaxanthin)
and carotenes (nonpolar  carotenoids  such as  α-carotene,  β-carotene,  and lycopene).  In
contrast to carotenes which are metabolised by BCO1 and retained in the cytoplasm, the
enzyme  BCO2  is  associated  with  the  inner  mitochondrial  membrane  and  metabolises
xanthophylls (which accumulates in the inner mitochondrial membrane) into long-chain apo-
carotenoids.  BCO2 functions as a key regulatory enzyme that prevents toxicity caused by
carotenoid accumulation and loss of BCO2 function is associated with the development of
mitochondrial  oxidative  stress  and  metabolic  diseases  . The  uptake,  distribution  and
metabolism  of  carotenoids  have  been  attributed  to  the  activities  of  different  protein
transporters (SR-BI, CD36, NPC1L1), digestion enzymes (PNLIP, CES), cleavage enzymes
(BCO1/2),  intracellular  transporters  (FABP2)  and  receptors  (LPL,  APOC/E,  LDLR).  It  is
predicted that carotenoids are widely bioavailable . At a molecular level zeaxanthin not only
attenuates lipid oxidation by scavenging mitochondrial ROS but also promotes mitochondrial
biogenesis . The oxocarotenoids are effective modulators of the physical properties of both
natural  and  model  membranes,  increasing  their  rigidity  and  thermostability  .   Oxo-
carotenoids stabilise membranes to a greater extent than β-carotene; they are incorporated
into bilayers and span the membrane with their lipophilic core, being further anchored in the
aqueous area with –OH groups, thus functioning like a molecular rivet .
Several  intervention  studies  have  investigated  whether  carotenoids  improve  vascular
outcomes.  Despite  the  lack  of  benefit  of  astaxanthin  on  vascular  risk  factors  in  renal
transplant patients , a systematic review and meta-analysis has confirmed that increasing
tomato  and  lycopene  intake  has  positive  effects  on  blood  lipids,  blood  pressure  and
endothelial function . Smaller studies have also identified positive effects of lutein in early
atherosclerosis . Previously, we have shown that a decrease of circulating  carotenoids and
tocopherols  was  associated  in  correlated  with  increased  protein  and  lipid  oxidation   in
dementia and vascular  disease patients that was correlated with the degree of cognitive
impairment .  In the MARK-Age study, lower levels of β-cryptoxanthin and zeaxanthin were
found among 2220 randomly recruited age-stratified persons, in those who were physically,
cognitively  or  psychologically  frail  [34].  Notably,  carotenoid concentrations were inversely
associated with the risk of being cognitively frail after adjusting for confounders .
Vascular disease is a common co-morbidity with dementia.  Evidence from cross-sectional
and  observational studies has grown for an association between elevated serum cholesterol
in mid-life and later development of dementia. Furthermore, chronic low-grade inflammation
relates to age-related cognitive impairment . The epigenetic oxidative redox shift  theory of
ageing proposes that sedentary behavior associated with age triggers an oxidised redox shift
and  impaired  mitochondrial  function  inducing  an  epigenetic  vicious  circle  that  promotes
inflammation .
Conversely,  optimal  nutrition  may  negatively  influence  dementia  risk  through  epigenetic
mechanisms.  The  “LEARn”  (latent  early  life-associated  regulation)  model  suggests  that
environmental stress – likely and often oxidative stress and/or nutritional imbalance - marks
a gene which later during life and in the presence of a secondary trigger, e.g. inflammation, it
will  be expressed aberrantly causing overt  pathology .  Preliminary studies on the role of
vascular-  and  lifestyle-related  preventive  strategies  show  that  vascular  risk  control  and
lifestyle improvement are indeed able to slow down the progression of cognitive impairment .
Plasma levels of several lipophilic antioxidant micronutrients are significantly associated,
independently  of  fruit  and vegetable intake,  with  validated,  accurate measures of  both
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cognitive and physical performance in persons with mild cognitive impairment (MCI). This
represents a further step in the field of nutritional cognitive neuroscience. 
Taken together, while carotenoids are promising phytonutrients that may limit vascular co-
morbidities,  this  remains  to  be  demonstrated  clinically.  The  underlying  mechanisms  of
individual  oxocarotenoids  and  their  interactions  with  mitochondria  and  inflammatory
pathways remain to determined.  In light of the increasing attention towards the nutritional
cognitive  neuroscience  of  carotenoids  [43,  44],  the  use  of  computerised  measures  of
cognitive  performance  might  be  further  implemented  in  future  studies  investigating  their
effects on cognitive and physical impairment.  
Overall conclusion
Inflammation associates with ROS/RNS production and with changes to the (oxy)lipidome.
(Per)oxidised lipids  are central  mediators in  the initiation  and resolution of  inflammation.
Generalised targeting with antioxidants such as tocopherols as a primary prevention in age-
related, inflammatory vascular disease has not proven successful. A more nuanced view is
emerging where ROS/NO production is desirable during early phases of inflammation and
for resolution. Indeed, the cell-targeted amplification of ROS in neutrophils may be required
in  some  circumstances   to  promote  resolution.  Phytochemicals  that  promote  resolving
oxylipid mediators and improve mitochondrial  quality control merit further investigation as
inhibitors of underlying sterile inflammation and to mitigate age-related vascular disease. 
20
Table 1





















































Non-canonical   
inflammasome 
pathway, TLR4
Decrease in IL-1β 









































HEK = hamster embryonic kidney cells
21
Figure Legends
Figure 1. Key mediators and cells involved in physiological and sterile inflammation
responses 
Figure 2. Innate immune recruitment to inflammatory sites; oxidised phospholipids
contribute to the chemotactic gradient  for  recruitment of inflammatory cells.  Their
local production in the mitochondria results in impaired mitochondrial  activity and
failure to remove damaged mitochondria exacerbates ROS production.  MtDNA and
OxPL enhance inflammasome activation and pro-inflammatory cytokine release.
Figure 3. Monocyte and macrophage phenotype and metabolism
Figure  4:  Cellular  distribution  of  oxysterols. Cellular  cholesterol  is  maintained by
regulatory mechanisms that control synthesis, uptake, metabolism and efflux. Cells
uptake  cholesterol  and  oxysterols  packed  lipoproteins  aided  by  many  membrane
receptors,  such as LDL receptor (LDLR) family, EBI2 ,  G-protein coupled receptor,
GPR17, C-X-C motif chemokine receptor 2 (CXCR2) and scavenger receptors. Inside
the cell, endosomes containing cholesterol/oxysterol are transported to Endoplasmic
reticulum  (ER)  mitochondria  or  peroxisomes.  Within  ER,  sterols  are  further
metabolised with help of many protein complexes including, oxysterol binding protein
(OSBP), OSBP-related proteins (ORPs), the cellular nucleic acid binding protein, the
sterol  regulatory  element  binding  protein  (SREBP),  insulin  induced  gene  protein
(INSIG) and Niemann-Pick protein C1 (NPC1). These metabolic activities within ER and
golgi  transfer  signals  to  nucleus  either  to  up-  or  down  regulate  endogenous
cholesterol synthesis via 3-hydroxy-3-methylglutaryl CoA reductase (HMGR) pathway.
Cellular cholesterol and oxysterol levels are also sensed a family of nuclear receptors
family;  Liver  X receptors (LXR),  Retinoid X receptor (RXR),  Retinoic  acid receptor
(RAR)-related  orphan  proteins  (RORα,  RORβ and RORγ)  and Estrogen receptor  α
(ERα). Activation of these transcription factors upregulate multiple genes involved in
cellular  cholesterol  homeostasis,  including  ATP-binding  cassette  transporter  A1
(ABCA1),  ATP binding cassette transporter  G1 (ABCG1),  and APOE. Mitochondrial
translocator protein (TSPO) has high affinity for cholesterol and uptake cholesterol
from  ER  or  from  lipid  droplets.  Steroidogenic  acute  regulatory  protein  (StAR)
transport cholesterol from the outer to inner membrane in mitochondria. Peroxisome
proteins  ATP-binding  cassette  transporter  D1  (ABCD1)  and  acyl-CoA  oxidase  1
(ACOX1) are also involve in transport of cholesterol and oxysterols.  
Figure 5. Lipid-derived mediators of inflammation are key players that drive both pro-
inflammatory  and  anti-inflammatory  and  pro-resolving  responses.  Infiltration  of
neutrophils  from blood vessels  into  the  site  of  injury,  and  later  pro-inflammatory
macrophages (M1 macrophages), is supported by leukotriene B4 and prostaglandin
F2α.  Resolution  phase  is  initiated  by  the  synthesis  of  prostaglandins  that  induce
“class switch” from pro-inflammatory (LtB4,  PGF2α) to the specialised pro-resolving
mediators (SPM,  such as lipoxins,  resolvins,  protectins  and maresins).  Their  dual
acting nature stops neutrophils from further infiltrating to the sites of injury, while
supporting chemotaxis of pro-repair macrophages (M2 macrophages), phagocytosis
of apoptotic material, and their exit via lymphatics.  
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ABCD1 ATP-binding cassette transporter D1
ABCA1 ATP-binding cassette transporter A1
ABCG1 ATP binding cassette transporter G1
ACOX1 acyl-CoA oxidase 1
ADME absorption,  distribution,  metabolism,  and
excretion
ALX lipoxin A4 receptor
AP1 Activator Protein 1
COX cyclooxygenases
CXCR2 C-X-C motif chemokine receptor 2
D6D Delta 6 desaturase
DAMPS damage-associated molecular patterns
DHA Docosahexaenoic acid
EBI2 Epstein-Barr-virus-induced  G-protein
coupled receptor 2
ER Endoplasmic reticulum
Gclm glutamate cysteine ligase
GPCR G protein coupled receptors
HIF1α Hypoxia-inducible factor 1-alpha
HMGR 3-hydroxy-3-methylglutaryl CoA reductase
Ho-1 haemoxygenase 1
IC50 inhibitory concentration
INSIG insulin induced gene protein
KEAP-1 Kelch Like ECH Associated Protein 1
LEARn latent early life-associated regulation
LC3 light chain 3








LXR  Liver X receptors
lyso-PC lysophosphatidyl choline
MCI mild cognitive impairment
NADH Nicotinamide adenine dinucleotide
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NADPH nicotinamide  adenine  dinucleotide
phosphate oxidase
NET neutrophil extracellular traps
NLR NOD-like receptors
NLRP nucleotide-binding  domain,  leucine-rich-
containing family, pyrin domain-containing
•NO nitric oxide
•NO2 nitrogen dioxide
NOD nucleotide-binding oligomerization domain
NOS nitric oxide synthases
NOX (NADPH) oxidase
NPC1 Niemann-Pick protein C1
Nrf2 nuclear factor erythroid 2-related factor 2

















PPARγ peroxisome  proliferator-activated  receptor
gamma
PUFA polyunsaturated fatty acids
PRR pattern recognition receptors
ResE1 resolvin E1
ResE2 resolvin E2
RNS reactive nitrogen species
RXR Retinoid X receptor
RAR Retinoic acid receptor
ROS reactive oxygen species
SOD2 superoxide dismutase-2
SIRT sirtuin
SPM specialised pro-resolving lipid mediators of
inflammation
SREBP sterol regulatory element binding protein
StAR Steroidogenic acute regulatory protein
TBXA2R thromboxane A2 receptor
TGFβ Transforming growth factor beta
TLR Toll-like receptor
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